3[1]Reaven GM. Role of insulin resistance in human disease. Diabetes, 1988, 37:1595-1599.
4[2]Marchesini G, Brizi M, Bianchi G,et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabe tes, 2001, 50: 1844-1850.
5[3]Norman RJ, Kidson WJ, Cuneo RC, et al. Metformin and intervention in polycystic ovary syndrome. Endocrine Soci ety of Australia, the Australian Diabetes Society and the Australian Paediatric Endocrine Group. Med J Aust, 2001,174: 580-583.
6[4]Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular mor bidity and mortality associated with the metabolic syn drome. Diabetes Care, 2001, 24: 683-689.
7[8]Groop L, Orho-Melander M. The dysmetabolic syndrome, J Intem Med, 2001, 250: 105-120.
8[9]Wilson SH, Kennedy FP, Garratt KN. Optimisation of themanagement of patients with coronary heart disease and type 2 diabetes mellitus. Drugs Aging, 2001, 18: 325-333.
8de Groot H , Brecht M, Machicao F. Evidence for a factor protective against hypoxic liver parenchymal cell injury in a protein-free blood extract [J]. Research Communications in Chemical Pathology And Pharmacology [Res Commun Chem Pathol Pharmacol, 1990,68 (1):125-128.
9Kuninaka T, Senga Y, Senga H, et al. Nature of enhanced mitochondrial oxidative metabolism by a calf blood extract[J].Journal of Cell Physiol , 1991, 146(1) : 148-155.
10Obermaier KB, Muhlbacher C, Mushack J, et al. Further evidence for a two-step model of glucose-transport regulation[J].Biochem J, 1989,261 (3) : 699.
